Yale Cancer Center

Yale Cancer Center will share data for breakthrough and emerging cancer treatments at the AACR Annual Meeting.

Amer Zeidan, MBBS, MHS, has been appointed inaugural chief of the Division of Hematologic Malignancies at Yale Cancer Center.

Non-small cell lung cancer, with an EGFR mutation, tends not to respond well to immunotherapy treatments, including durvalumab.

Although use of immunotherapy near the end of life has increased over time, a closer look at the benefit of this in those with advanced cancers is needed.

A new study led by Yale scientists shows that the activity of a portion of a human papillomavirus protein does not depend on its amino acid sequence or composition.

Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology, June 2nd to June 6th at McCormick Place in Chicago, Illinois.

Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.

Barbara Burtness, MD, has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.

Continued treatment for patients with cancer near end of life delays conversations about goals of care and hospice enrollment, escalates costs, and may adversely affect the quality of care patients receive.

An analysis by Yale Cancer Center researchers identified accelerated genetic aging in breast tissue adjacent to breast cancer tumors.

Scientists at Yale Cancer Center have found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.

The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non–small cell lung cancer.

Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicates there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.

Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.

Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme, the most common and most aggressive type of malignant brain tumor.

The National Cancer Institute recently awarded Yale Cancer Center and Yale School of Public Health a new U01 cooperative agreement grant to support research into the impact of diet and exercise for women with ovarian cancer.

A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development.

New research led by Yale Cancer Center shows the creation of a next-generation CRISPR-Cas9 “off-switch” and precision tool to aid safe gene editing therapeutics in patients.

Yale Cancer Center held its annual Conclave award ceremony virtually on February 15 to celebrate scientific and caregiver accomplishments in 2021

New research led by Yale Cancer Center scientists shows less than a third of older patients with chronic myeloid leukemia had optimal laboratory monitoring and only two-thirds were adherent to TKI therapy during the first year after diagnosis.

New research led by Yale Cancer Center revealed White patients had significantly more telemedicine visits compared with Black patients for hematologic cancer care during the COVID-19 pandemic.

Ian E. Krop, MD, PhD, has been appointed chief clinical research officer, associate cancer center director for clinical research, and director of the Yale Cancer Center Clinical Trials Office.